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The human ABCG2 multidrug transporter provides protection against numerous toxic compounds and causes multidrug resistance in cancer.
Here we examined the effects of changes in membrane cholesterol on the function of this protein. Human ABCG2 was expressed in mammalian
and in Sf9 insect cells, and membrane cholesterol depletion or enrichment was achieved by preincubation with beta cyclodextrin or its cholesterol-
loaded form. We found that mild cholesterol depletion of intact mammalian cells inhibited ABCG2-dependent dye and drug extrusion in a
reversible fashion, while the membrane localization of the transporter protein was unchanged. Cholesterol enrichment of cholesterol-poor Sf9 cell
membrane vesicles greatly increased ABCG2-driven substrate uptake, substrate-stimulated ATPase activity, as well as the formation of a catalytic
cycle intermediate (nucleotide trapping). Interestingly, modulation of membrane cholesterol did not significantly affect the function of the R482G
or R482T substrate mutant ABCG2 variants, or that of the MDR1 transporter. The selective, major effect of membrane cholesterol on the wild-type
ABCG2 suggests a regulation of the activity of this multidrug transporter during processing or in membrane micro-domain interactions. The
experimental recognition of physiological and pharmacological substrates of ABCG2, as well as the fight against cancer multidrug resistance may
be facilitated by demonstrating the key role of membrane cholesterol in this transport activity.
© 2007 Elsevier B.V. All rights reserved.Keywords: ABC transporters; ABCG2 transport activity; Multidrug resistance; Membrane cholesterol; ATPase activity1. Introduction
ABCG2 is a member of the ABC multidrug resistance
protein family, a plasma membrane glycoprotein, present in
many human tissues, including the placenta, liver, kidney, and
intestine. The tissue distribution of ABCG2 suggests that its
main physiological role is the regulation of intestinal absorption
and biliary secretion of potentially toxic xenobiotics. ABCG2
may also be a protective element in the maternal–fetus and inAbbreviations: ABC transporters, ATP binding cassette transporters; CD,
cyclodextrin; C-CD, cyclodextrin loaded with cholesterol; S-CD, cyclodextrin
loaded with sitosterol; EKI, EKI-785 tyrosine kinase inhibitor; ESG, estradiol
17-beta glucuronide; E3S, estrone 3-sulfate; MDR1, multidrug resistance
protein 1; MRP1, multidrug resistance associated protein 1; MTX, methotrexate;
PheA, Pheophorbide A; R123, Rhodamine 123
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doi:10.1016/j.bbamem.2007.06.026the blood–brain barrier, and the protein is present at high levels
in stem cells, currently with an unknown physiological function
[1–5].
ABCG2 is also used by tumor cells to fight anticancer
medicines, as ABCG2 overexpression provides an active pro-
tection against a number of chemotherapeutic drugs. ABCG2
expression was found in various leukemias, in the tumors of the
ovary, lung, breast, colon and gastric cancer. The anticancer
cytotoxic compounds extruded by ABCG2 include mitoxan-
trone, topotecan, camptothecin, irinotecan, flavopiridol, as well
as methotrexate and its polyglutamated metabolites [1,3,6–8].
ABCG2 is an ABC “half-transporter”, which requires homo-
dimerization for its transport function [9]. Similarly to all ABC
multidrug transporters, drug extrusion by ABCG2 is closely
coupled to a drug-stimulated, vanadate-sensitive ATPase acti-
vity, which requires the presence of Mg2+ ions [9,10]. During its
substrate transport and ATP hydrolytic cycle ABCG2 occludes
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presence of vanadate. The direct, ATP-dependent transport of
several substrates of ABCG2, including methotrexate, glucur-
onidated or sulfated estrogens and xenobiotics, has been
demonstrated [11–14].
The R482G and R482T mutant variants of ABCG2, found
only in drug-selected tumor cells, show a significantly altered
drug resistance pattern, as compared to the wild-type protein.
These mutants efficiently transport various anthracycline
derivatives or Rhodamine 123, while the wild-type ABCG2
shows very little transport activity for these compounds. In
contrast, the R482G and R482T variants practically do not
transport methotrexate or drug conjugates [14–17]. There are
several polymorphic variants of ABCG2 present in large
percentage in the human population (e.g. V12M, Q141K), and
the possible alterations in the transport capacity and substrate
handling of these variants have been examined in numerous
experimental systems [18–24].
The functional regulation of the ABCG2 transport activity is
relatively unexplored as yet. There are several data for the
modulation of ABCG2 transcription during cell differentiation,
cytotoxic exposure, or hypoxia, as well as after exposure to
hormones or hormone derivatives [25–27]. It has also been
proposed that estrogen may have a post-translational regulatory
effect by altering the biosynthesis and maturation of ABCG2
[28]. Membrane cholesterol has been implicated in the
regulation of many membrane proteins, including several ABC
transporters, and membrane micro-domains with increased
cholesterol content have been suggested to play a role in such
a regulation [29,30]. In the case of ABCG2 one study found a
significant cholesterol stimulation of its ATPase activity, when
the protein was expressed in Lactococcus bacteria [31]. The
authors suggested that ABCG2 may be directly involved in
cholesterol transport. However, no detailed studies are available
as yet for the transport and ATPase modulation of ABCG2
activity by cholesterol in eukaryote model systems.
In the present experiments we have examined the effects of
membrane cholesterol modulation on the function of the human
ABCG2 protein. We followed the function and localization of
this transporter in intact mammalian cells, depleted from, or
loaded with cholesterol. We also studied the direct transport and
ATPase activity, as well as the formation of a catalytic
intermediate of the human ABCG2, expressed in recombinant
baculovirus-infected Sf9 cells. Sf9 cell membranes contain
significantly lower cholesterol than mammalian cell membranes
[32] and proteins sensitive to membrane cholesterol have
different activities when expressed in this system [33,34].
Thus Sf9 cell membrane preparations provide an excellent
opportunity to directly explore the effects of increasing
membrane cholesterol on the characteristics of a given mam-
malian membrane protein.
Our experiments show a major effect of membrane
cholesterol on the activity of ABCG2. We found that cholesterol
depletion strongly inhibited ABCG2-dependent drug/dye extru-
sion in intact mammalian cells in a reversible fashion, while
cellular cholesterol loading increased this transport activity.
There was no effect of cholesterol loading or depletion on thegeneral membrane localization of ABCG2 in these short-term
experiments. In isolated Sf9 cell membranes cholesterol loading
greatly and specifically increased the maximum transport
capacity and ATPase activity of ABCG2, and increased the
rate of the formation of a catalytic intermediate. Interestingly,
membrane cholesterol modulation under the same conditions
had only a negligible effect on the activity of ABCG2–R482G
and ABCG2–R482T mutant variants, or that of the MDR1
multidrug transporter. These data indicate a significant,
selective, and reversible modulation of ABCG2 activity by
membrane cholesterol.
2. Materials and methods
2.1. Cell and membrane preparations
Mammalian HEK and A431 cells, selectively overexpressing the human
ABCG2 or its mutant variants, were prepared either by transfection and selection
as described in [23], or by retroviral transduction as described in [35]. For Sf9 cell
expression, cDNAs of human ABCG2 and its mutant variants were cloned into
recombinant baculovirus transfer vectors, the insect cells were cultured, and
infectedwith the baculoviruses as described in [14]. Virus-infected Sf9 cells were
harvested, cell membranes were isolated, and membrane protein concentrations
were determined as described previously [9,14,36]. The membrane preparation
was optimized to yield high amount of inside-out vesicles in these preparations,
and the constant amount of these vesicles was assured by measuring endogenous
calcium transport activity, as described in refs. [14,17].
The level of ABCG2 expression was detected by immunoblotting, using the
BXP-21 monoclonal antibody and the enhanced chemiluminescence technique
(ECL, Amersham Biosciences). Quantitation of ABCG2 expression was
achieved by densitometry of the immunoblots.
2.2. Cholesterol loading and depletion
For the modulation of membrane cholesterol content in mammalian cells, we
used cyclodextrin pretreatments. In case of intact cells (see Figure legends) 106–
107 suspended cells were preincubated at 37 °C for 20–30 min in 1 ml serum-
free media, containing 2–4 mM of random methylated beta (RAMEB)
cyclodextrin (CD, CycloLab), either without lipids or loaded with cholesterol
(C-CD, cholesterol content 4.4%). The cells were washed to remove CD or free
cholesterol and used for further transport experiments within 1 h. Cell viability
was tested by trypan-blue exclusion or propidium-iodide staining, indicating
that CD or C-CD treatments did not significantly increase the number of dead
cells. Cholesterol content of the cells was measured by the enzymatic (Molecular
Probes, Amplex Red) cholesterol assay kit.
For cholesterol loading of Sf9 cell membranes, we used two different
techniques. In experiments shown in Fig. 3A, isolated membranes were prepared
as described in [17], and then preincubated for 10 min at 4 °C with the indicated
concentrations of CD–lipid complexes, including cholesterol-CD (cholesterol
content 4.4%), sitosterol-CD (sitosterol content 1.9%), ergosterol-CD (ergos-
terol content 2%), or hydrocortisone–CD (hydrocortisone content 10.2%),
prepared by CycloLab technology. The following transport or ATPase
experiments were then performed by directly using these membrane prepara-
tions. In most experiments, during the course of the membrane preparation,
before the final centrifugation step, the isolated membranes were incubated for
20 min at 4 °C with 2–4 mM of various RAMEB cyclodextrin preparations, and
then cyclodextrin complexes were eliminated by a 20× dilution and a following
high speed (100,000×g) centrifugation. Membrane preparations were stored at
−80 °C in aliquots and cholesterol content was estimated by the Amplex red kit,
described above.
2.3. ABCG2 activity measurements
In intact mammalian cells ABCG2 activity was measured in various assay
systems. Hoechst 33342 dye uptake in a fluorescence spectrophotometer was
Fig. 1. Effect of cholesterol depletion or cholesterol loading on the activity of
ABCG2 in intact HEK and A431 cells. Panel A. Effect of cyclodextrin (CD) or
cholesterol-cyclodextrin (Chol-CD) pre-treatment on the Hoechst dye uptake
activity factor in HEK cells, as measured in a fluorescence spectrophotometry
assay. HEK cells, expressing the humanwild-type ABCG2, the ABCG2–R482G
variant, or the MDR1 protein, were pretreated in HPMI medium by 4 mMCD or
4 mM C-CD for 30 min at 37 °C, then washed twice to eliminate cyclodextrin.
Hoechst dye (2 μM) accumulation was continuously measured at 37 °C in HPMI
medium in a fluorescence spectrophotometer for 8 min, then 1 μMKo143 (to the
ABCG2 expressing cells) or 30 μM verapamil (to the MDR1 expressing cells)
was added, and Hoechst fluorescence was measured for another 8 min. Dye
extrusion activity factor was calculated based on the difference between the
control uptake rate and that in the presence of inhibitor, as described in Materials
and methods. The mean values±SD are presented. Empty columns: untreated
cells, light gray columns: cyclodextrin (CD) pretreated cells, dark gray columns:
cholesterol-cyclodextrin (C-CD) pretreated cells, striped columns: cyclodextrin
(CD) pretreated, and then cholesterol repleated cells by cholesterol-cyclodextrin
(C-CD) treatment. Panel B. Effect of cyclodextrin (CD) or cholesterol-
cyclodextrin (Chol-CD) pre-treatment on the Hoechst dye uptake activity factor
in A431 cells, as measured in a fluorescence spectrophotometry assay. The A431
cells were treated and dye accumulation measured as described for panel A.
Empty columns: untreated cells, light gray columns: cyclodextrin (CD)
pretreated cells, dark gray columns: cholesterol-cyclodextrin (C-CD) pretreated
cells, striped columns: cyclodextrin (CD) pretreated, and then cholesterol
repleated cells by cholesterol-cyclodextrin (C-CD) treatment.
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described [17,37], that is the initial uptake rate (without inhibitor) was subtracted
from the rate measured in the presence of a specific inhibitor, and divided by the
uptake rate measured with the inhibitor. Mitoxantrone (MX) or Pheophorbide A
(PheA) uptake was measured by flow cytometry, essentially as described in [38].
PheA uptake was followed for 12 min after the addition of 0.5 μM PheA, either
in the absence or in the presence of 1 μM Ko143. Cellular PheA fluorescence
was determined at excitation and emission wavelengths of 635 and 661 nm,
respectively, in a FACSCalibur cytometer. Dead cells were excluded on the basis
of propidium iodide staining.
In isolated Sf9 cell membranes vanadate-sensitive ATPase activity was
measured as described in [39], using 20 min incubation times at 37 °C. MgATP-
dependent uptake of 3H-labeled methotrexate (MTX) and 3H-labeled estradiol-
17-beta glucuronide (ESG) in inside-out membrane vesicles was measured by a
rapid filtration method as described [14,40], using 5-min incubations at 37 °C.
We ensured that during this time period the rate of vesicular substrate uptake was
linear, allowing to estimate the kinetic values. ATP-dependent transport activity
of ABCG2 was determined by subtracting the uptake measured in the presence
of MgAMP. MgATP-dependent transport by ABCG2 was fully inhibited by
Ko143 (see Figures). MgATP-dependent Rhodamine 123 uptake by Sf9
membrane vesicles was measured by flow cytometry, by using the parameters
described for Rhodamine fluorescence [14], and selecting the vesicle population
based on FSC/SSC parameters. R123 uptake was followed in the presence of
1 μM R123, by taking 30 second time points for 5 min either at 37 °C or 22 °C.
Again, the addition of MgAMP and Ko143 served as negative controls.
Formation of the catalytic intermediate (“nucleotide trapping”) by the
ABCG2 protein was measured as described in [17]. In brief, control or
cholesterol-loaded Sf9 membranes (150 μg/assay) were incubated with 2.5 μM
Co-8-azido-ATP (containing alpha-32P-8-azido-ATP) for 2 or 5 min, then
washed with ATP-containing media and UV-irradiated on ice. After gel-
electrophoresis and electroblotting the labeled bands were visualized by
Phospho-Imager and identified by immunoblotting, using the BXP-21 anti-
ABCG2 antibody, as well as by Coomassie staining.
2.4. Confocal microscopy
HEK cells stably transfected with ABCG2 (wt) or ABCG2–R482G were
seeded onto eight-well Nunc Lab-Tek II Chambered Coverglass (Nalge Nunc
International, Rochester, NY) at 3×104 per well cell density, and grown for 48 h
in D-MEM containing 10% FCS. Prior to the microscopy studies, the cultures
were incubated with serum-free D-MEM containing 2.5 mM CD or 2.5 mM
cholesterol-CD, for 20 min at 37 °C. For cholesterol repletion, the cells were first
subjected to 2.5 mM CD for 20 min, then to 2.5 mM C-CD for an additional
20 min at 37 °C. Following the preincubation, the cells were gently washed,
placed into serum free D-MEM, and studied by an Olympus FV500-IX confocal
laser scanning microscope using an Olympus PLAPO 60× (1.4) oil immersion
objective (Olympus Europa GmbH, Hamburg, Germany) at room temperature.
The blue fluorescence was acquired at 405 nm excitation. The samples were
subjected to 2 μM Hoechst dye, and after a 120 sec incubation time, 1 μM
Ko143 was added to the medium. The activity factor was determined from the
steady state fluorescence accumulation rates before and after Ko143 addition
(see Fig. 1B).
For immunofluorescence studies the cells were seeded, cultured and
preincubated with CD or C-CD as described above. For cell surface labeling,
the cells were gently washed with Dulbecco's modified PBS (DPBS), and fixed
with 1% paraformaldehyde in DPBS for 15 min at room temperature, and then
blocked for 1 hr at room temperature in DPBS containing 0.5% bovine serum
albumin. The samples were then incubated for 1 h at room temperature with the
monoclonal anti-ABCG2 antibody, 5D3, conjugated with allophycocyanin
(APC), diluted 5× in DPBS containing 0.5% BSA, finally washed with DPBS.
For immunostaining of permeabilized cells, the CD- or C-CD pretreated samples
were gently washed, and fixed with 4% paraformaldehyde in DPBS for 15 min
at room temperature. After few washes with DPBS, the cells were further fixed
and permeabilized in pre-chilled methanol for 5 min at −20 °C. Following
further washing steps, the cells were blocked for 1 hr at room temperature in
DPBS containing 2% bovine serum albumin, 1% fish gelatin, 0.1% Triton-X
100, and 5% goat serum (blocking buffer). The samples were then incubated for
1 hr at room temperature with the monoclonal anti-ABCG2, BXP-21 diluted100× in blocking buffer. After washing with DPBS, the cells were incubated for
1 hr at room temperature with Alexa Fluor 488-conjugated goat anti-mouse IgG
(H+L) diluted 250× in blocking buffer. As isotype controls, APC-conjugated
mouse IgG2b (5 μg/ml) and mouse IgG2a (2.5 μg/ml) plus Alexa Fluor 488-
conjugated goat anti-mouse IgG (1:250) were used. The APC-conjugated 5D3,
the BXP-21, and the anti-mouse secondary antibodies were obtained from R&D
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Molecular Probes (Eugene, USA), respectively. The APC-conjugated mouse
IgG2b, and the mouse IgG2a isotype controls were purchased from eBioscience
(San Diego, USA) and DAKO Cytomation (Glostrup, Denmark), respectively.
The stained samples were studied with confocal microscope specified above.
The green and deep red fluorescence were acquired above 505 nm and 650 nm,
using 488 nm and 633 nm excitations, respectively.
All documented measurements were carried out in at least two independent
membrane preparations, at least in triplicates.3. Results
3.1. Experiments with intact mammalian cells
For modulation of membrane cholesterol in intact mamma-
lian cells, we applied mild treatments with beta cyclodextrin
(CD), or with its cholesterol-loaded form (C-CD). Cyclodextrin
complexes have been shown to be rapidly and effectively
transferring cholesterol to and from cells and biological mem-
branes [41,42].
In the experiments documented in Fig. 1A, we examined the
effect of cholesterol depletion or cholesterol loading, respec-
tively, on fluorescent dye extrusion from ABCG2-expressing
intact HEK cells. The Hoechst 33342 dye is a good substrate of
both the wild-type and the R482G or R482T mutant variants of
ABCG2 [1,3], as well as of the MDR1 transporter [4]. This dye
becomes fluorescent only inside the cells, when bound to DNA,
thus increase in fluorescence directly reflects dye accumulation.
In control cells this uptake is fast and not influenced by the
addition of transporter inhibitors. The expression of ABCG2, its
R482G mutant form, as well as MDR1 strongly decrease
Hoechst dye accumulation. In the case of the addition of a
specific inhibitor there is a major increase in rate of dye
accumulation, reaching the level seen without transporter
overexpression. As specific inhibitors, in the case of ABCG2
we used 1 μM Ko143, while in the case of MDR1 we applied
30 μM verapamil. The activity factor calculations (see Methods
and 17) provide a quantitative estimate of the transporter
activity in intact cells. As shown below in the isolated mem-
brane experiments (see Fig. 3), the applied Ko143 concentration
resulted in a full inhibition of ABCG2, independent of the
membrane cholesterol concentrations.
Fig. 1 shows the effect of cholesterol depletion or loading on
the activity factors calculated for Hoechst 33342 dye extrusion
at 37 °C in ABCG2-expressing HEK (Panel A) and A431 cells
(Panel B), respectively, measured in a fluorescence spectro-
photometer. For demonstrating the effect of cholesterol we
chose here cells expressing medium levels of the transporters,
thus having a Hoechst transport activity factor between 0.4 and
0.7.
As documented in Fig. 1A, cholesterol depletion of HEK
cells by 4 mM CD for 30 min at 37 °C practically eliminated
Hoechst dye extrusion by the wild-type ABCG2 (the activity
factor decreased from 0.54 to 0.05), while this treatment had no
effect on dye extrusion in ABCG2–R482G expressing, or
MDR1 expressing HEK cells. The effect of additional
cholesterol loading by C-CD was not significant in these
experiments in any of the above cell types.It is also important to note, that the applied cholesterol
depletion or cholesterol loading did not significantly affect the
rate of Hoechst 33342 dye accumulation in the control HEK or
A431 (see below) cells. Also, as measured by trypan-blue or
propidium iodide exclusion, this mild pre-treatment did not
increase the number of dead cells in the preparation (cell
viability was over 85% in each experiment), and preserved the
function of the ABCG2 mutant variants or other ABC-
multidrug transporters (see also below).
Based on the enzymatic cholesterol measurements (see
Methods), the original total cholesterol content in the HEK cells
used in this study was 7.71±1.1 μg/mg total protein, and this
cholesterol content could be decreased by about 25%, to 5.71±
0.9 μg/mg total protein by 4 mM CD preincubation, or
increased to 12±1.2 μg/mg total protein, that is to about 150%,
by 4 mM C-CD incubation.
When examining the possible reversibility of cholesterol
depletion, we depleted HEK-ABCG2 cells from cholesterol for
30 min, as described above, and then after one washing step
further incubated these cells for 20 min in a serum-free medium,
or in a medium containing 4 mM Cholesterol-CD. When
measuring Hoechst dye uptake in these cells we found that the
original activity factor of 0.54±0.06 decreased to 0.05±0.04
during CD treatment, and the activity factor was increased to
0.58±0.07 after cholesterol reloading. Thus, the modulation of
ABCG2 transport activity by cholesterol was fully reversible.
As shown in Fig 1B, we have also performed Hoechst dye
uptake experiments in ABCG2-expressing A431 tumor cells,
overexpressing ABCG2 after a retroviral transduction [35]. In
these cells the results were essentially similar to those obtained
in HEK cells. The activity factor in the ABCG2 expressing
A431 cells decreased to very low levels after 30 min cholesterol
depletion, and increased to slightly above the control values
after cholesterol loading. Cholesterol repletion of cholesterol-
depleted cells restored the activity factor to the level of the
control cells. Thus cholesterol modulation of ABCG2 transport
activity in both HEK and A431 cells was also fully reversible
and selective for the wild-type protein.
In experiments not documented here in detail, we have
repeated these cellular transport experiments by measuring the
uptake of mitoxantrone (MX) and Pheophorbide A (PheA), both
transported compounds for both ABCG2 and its R482G variant,
by using flow cytometry. We found that after cholesterol
depletion the HEK cells expressing the wild-type ABCG2 had a
significantly lower extrusion capacity, while cholesterol deple-
tion had no effect on MX or PheA extrusion in HEK cells
expressing the R482 mutant variant.
In order to demonstrate the major effect of membrane
cholesterol on the ABCG2-dependent Hoechst dye transport in
intact cells, we performed similar experiments in a real-time
microscopic transport assay system, by using confocal micro-
scopy. Cellular Hoechst dye uptake was directly, in situ
followed under the microscope, and the changes in the rate of
dye uptake were analyzed by determining the mean fluores-
cence in a selected number [10–12] of cell nuclei.
As shown in Fig. 2A, left panel, after the Hoechst dye
addition, ABCG2-expressing HEK cells showed a low level of
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of the ABCG2 inhibitor, Ko143. CD-pretreatment of the
attached HEK cells significantly increased Hoechst dye uptake,
while C-CD pretreatment rather decreased this accumulation.
The actual dye accumulation rate was determined in a 60- to
120-s steady state uptake period, before and after the addition of
Ko143 (see Fig. 2A, upper right panel), and the activity factors
were calculated. The lower right panel shows that the activity
factor was significantly decreased in the CD-treated, while
increased in the C-CD treated cells. Moreover, the decrease in
activity factor caused by CD treatment was fully reversible upon
a following C-CD incubation. Again, dye extrusion activity by
the ABCG2–R482G variant was practically unaffected by CD
or C-CD treatment. These experiments confirm that Hoechst
33342 dye extrusion in HEK cells, expressing the wild-type
ABCG2, is strongly modulated by membrane cholesterol, while
Hoechst transport by the ABCG2–R482G variant is not affected
by this membrane lipid. Cell viability was unchanged in these
studies—when measured by propidium iodide exclusion,
viability was above 85% in all samples examined.
In order to examine the possible changes in ABCG2 local-
ization during cholesterol depletion, we have performed
immunostaining of the HEK cells by using confocal microscopy.
We used both a cell-surface reactive anti-ABCG2 monoclonal
antibody (5D3) [43], and another monoclonal antibody (BXP21)
[44], recognizing an intracellular epitope of ABCG2. As
documented in Fig. 2B, both antibodies detected exclusive
plasma membrane staining, both in the control, and in the CD-
treated, cholesterol-depleted cells. A similar picture was
observed in the cholesterol repleted HEK cells as well (not
shown).
These experiments strongly suggested that in intact cells
membrane cholesterol has a major effect on the wild-type
ABCG2 protein, while the morphology or the basic functions of
the cells were unaltered under the mild cholesterol depletion
applied. Moreover, the ATP-dependent transport by ABCG2-
R482G or MDR1 was also not significantly affected under these
conditions.
3.2. Experiments with isolated Sf9 cell membranes
In order to explore the molecular details of the cholesterol
effects observed in intact cells, ABCG2 and its R482G, R482T
mutant variants were expressed in Sf9 cells. Sf9 cells, as
compared to mammalian cells, contain low level of endogenous
membrane cholesterol, thus in this system a direct effect of
cholesterol loading can be better examined [32–34]. Sf9 cells
were engineered to express high amounts of the human ABCG2
variants, at about equal transporter protein levels [14]. More-
over, in isolated membranes of Sf9 cells both direct vesicular
transport, drug-stimulated ATPase activity and catalytic inter-
mediate formation (nucleotide trapping) could be examined
[17].
For cholesterol loading of Sf9 cell membranes we applied a
preincubation of the membranes at 4 °C with sterol-containing
beta cyclodextrin, followed by a removal of this agent during the
further centrifugation steps. The original membrane cholesterolcontent in our Sf9 cell membrane preparations was between 5
and 8 μg/mg membrane protein, and with 1–5 mM cholesterol-
cyclodextrin (C-CD) preincubation this cholesterol content
could be gradually increased up to 60–80 μg cholesterol/mg
membrane protein. As a comparison, we found that the
cholesterol content of the HEK or MCF7 human cell membrane
preparations was between 30 and 40 μg/mg membrane protein,
irrespective of the presence or absence of ABCG2 expression,
while isolated red cell membranes contain up to 100 μg
cholesterol/mg protein [45].
3.3. Vesicular transport studies
We carried out direct, ATP-dependent substrate transport
measurements by using isolated inside-out membrane vesicles
of ABCG2-expressing Sf9 cells [14,17]. In the first set of
experiments we studied the effects of various sterol–CD
complexes directly added to the membrane vesicles in a short
preincubation period at 4 °C (see Materials and methods).
Methotrexate (MTX) transport activity of the wild-type ABCG2
was measured at 100 μMMTX concentration, by the addition of
5 mM ATP in a 5 min incubation period at 37 °C. To correct for
any endogenous MTX transport activity, ABCG2-dependent
active MTX uptake was calculated by subtracting MTX uptake
measured in the presence of 1 μM Ko143, fully inhibiting
ABCG2.
As documented in Fig. 3A, the addition of 1–4 mM CD did
not have any significant effect of MTX transport activity.
However, Cholesterol-CD greatly increased ABCG2-dependent
MTX uptake in a concentration-dependent manner (we found a
maximum effect at 4 mMC-CD, data not shown in detail). There
was no such transport increase in the presence of 1-4 mM
sitosterol-CD or hydrocortisone-CD, while ergosterol-CD
actually slightly decreased ABCG2-dependent MTX uptake. It
has been shown earlier that all these sterol-CD complexes allow
a rapid exchange of sterol molecules with hydrophobic binding
materials [41].
In order to further investigate the effect of cholesterol loading
of Sf9 cell membranes, the following experiments were
performed by C-CD pretreated, cholesterol preloaded isolated
membrane preparations. In these experiments the preloaded
membranes, with stable membrane sterol content, could be
characterized in detail. As shown in Fig. 3B, preloading of the
membranes with cholesterol (C-CD) greatly increased the MTX
transport activity of the wild-type ABCG2, to yield a 15–20 fold
increase, when the initial membrane cholesterol was elevated to
65 μg cholesterol/mgmembrane protein.We found a similar large
increase in the ABCG2-dependent uptake of estradiol beta-17-
glucuronide (ESG—see below), and of estrone 3-sulfate (E3S—
not shown) in the Sf9 membrane vesicles after cholesterol
loading. We found that pretreatment with free cyclodextrin (CD)
did not significantly affect either the MTX (see Fig. 3), ESG or
E3G transport activity of the human ABCG2 protein. Also, when
we applied sitosterol (S) loaded CD (Fig. 3B—part 4) we found
no effect on the ABCG2-dependent transport activity. Ko143, a
specific inhibitor of ABCG2, abolished substrate transport both in
the control and cholesterol-loaded membrane vesicles.
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different substrate handling properties than the wild-type
protein. These mutant variants transport certain negativelyFig. 2. Confocal microscopy studies on the effect of membrane cholesterol on Ho
(A) Effect of cyclodextrin (CD) or cholesterol-cyclodextrin (Chol-CD) pre-treatment
assay. Cholesterol depletion or repletion by CD or C-CD was carried out in the surfa
serum free D-MEMmedium, as described in Materials and methods. Hoechst dye acc
ABCG2–R482G variant at 37 °C, and cellular dye content was estimated based on
difference between the control uptake rate and that in the presence of 1 μM Ko14
microscopy picture of HEK cells after 2 min of the Hoechst dye addition, and after an
right panel: nuclear Hoechst dye accumulation averaged in 12 cells during the experim
expressing the wild-type ABCG2 transporter,•—Hoechst dye uptake in cyclodextri
Hoechst dye uptake in cholesterol-cyclodextrin (C-CD) pretreated HEK cells, express
activity factors based on the average values obtained in at least 3 independent exper
(CD) pretreated HEK cells, dark gray columns: cholesterol-cyclodextrin (C-CD) pretre
second treatment with cholesterol-cyclodextrin (C-CD—see Materials and methods).
Effect of cyclodextrin (CD) pre-treatment on the immunolocalization of ABCG2 prot
was carried out as described for panel A. Untreated control, or cholesterol-depleted (C
Materials and methods, by the 5D3 monoclonal antibody, reacting with an extracellucharged compounds, e.g. MTX, ESG or E3S only with a very
low activity [17–21]. As shown in Fig. 3B, MTX transport by
the ABCG2–R482G variant was very low both in the controlechst dye uptake and ABCG2 localization in ABCG2-expressing HEK cells.
on the Hoechst dye uptake in HEK cells, as followed in a confocal microscopy
ce attached HEK cells by 2.5 mM CD or 2.5 mM C-CD for 20 min at 37 °C, in
umulation was measured in cells expressing the human wild-type ABCG2 or the
the fluorescence in selected regions of interests. Activity factor, based on the
3, was calculated as described in Materials and methods. Left panel: confocal
additional 4 min, following the addition of the ABCG2 inhibitor, Ko143. Upper
ent described above.▪—Hoechst dye uptake in the control, untreated HEK cells,
n (CD) pretreated HEK cells, expressing the wild-type ABCG2 transporter,▴—
ing the wild-type ABCG2 transporter. Lower right panel: the calculated ABCG2
iments. Empty columns: untreated HEK cells, light gray columns: cyclodextrin
ated HEK cells, striped columns: cyclodextrin (CD) pretreated HEK cells, after a
The mean values±SD are presented, the stars indicate significant differences. (B)
ein in HEK cells, followed by confocal microscopy. Cholesterol depletion by CD
D) ABCG2-expressing HEK cells were fixed and immunostained as described in
lar epitope, or by BXP21, reacting with an intracellular epitope of ABCG2.
Fig. 2 (continued).
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the MTX transport rate by the ABCG2–R482T variant was
below 50 pmol/mg membrane protein/min, irrespective of the
membrane cholesterol content. We found a similar lack of
significant ESG and E3S transport by the R482G and R482T
variants, irrespective of the cholesterol content of the membrane
vesicles (not shown).
It is important to note that we found little effect of sterol
loading or CD treatment on the endogenous ATP-dependent
calcium transport activity, used to estimate the vesicle content of
the Sf9 membrane preparations [17,40]. In the transport
experiments documented in this manuscript, CD or sterol-CD
treatment of the vesicles before the actual transport experiment
did not affect, while preloading with CD-cholesterol during
membrane preparation decreased the relative membrane
vesicular content by 20–30%, as measured by endogenous
calcium transport activity. Thus in these experiments the
increase in the ABCG2 transport activity is probably under-
estimated, as we did not perform a correction of the data based
on the calcium transport activity.
All these experiments suggest that the cholesterol effect was
specific for the wild-type ABCG2, and depletion of other lipid
constituents of the Sf9 cell membrane (e.g. by unloaded CD), an
increase in other related membrane sterols, or non-specific
permeability changes caused by various CD complexes could
not be accounted for the observed effects.
In the following experiments we examined how cholesterol
loading affected the kinetic parameters of MTX and ESG
transport by ABCG2. Fig. 4A shows the MTX concentration
dependence of the ABCG2-dependent MTX uptake in control,
and cholesterol-loaded Sf9 membrane vesicles, respectively. Inthe original, untreated Sf9 cell membrane vesicles (containing
6–8 μg cholesterol/mg membrane protein) the rate of MTX
uptake was low, with an apparent Vmax of about 0.5 nmol
MTX/mg membrane protein/min. In contrast, in the C-CD
pretreated vesicles (in this experiment containing 55 μg
cholesterol/mg membrane protein), MTX uptake had an
estimated Vmax of about 10 nmol MTX/mg membrane
protein/min. The apparent Km of MTX uptake was about
0.5 mM in both cases, but the proper determination of the Km
and Vmax values in these experiments was hindered by the low
solubility of MTX at higher than 3 mM concentrations. Fig. 4A
also documents that the R482G variant of ABCG2 had a very
low MTX transport activity, irrespective of the MTX concen-
trations examined.
When we examined the effect of membrane cholesterol on
the ATP concentration dependence of the MTX uptake in the
ABCG2-containing Sf9 membrane vesicles we found that,
irrespective of the membrane cholesterol content, MTX
transport had a saturable ATP-dependence, with an apparent
Km of 0.6–0.8 mM ATP and a maximum transport rate at about
5 mM ATP. These values are in agreement with the data in the
literature for the ATP-dependence of vesicular transport by
ABCG2 [17,21–23]. Again, neither the R482G, nor the R482T
variants showed any MTX transport activity, irrespective of the
ATP concentration or the cholesterol content of the Sf9 cell
membrane vesicles.
In the following experiments we examined the ESG
concentration dependence of ATP-dependent ESG uptake in
Sf9 membrane vesicles (Fig. 4B). Similarly to that seen for
MTX, in the cholesterol-loaded vesicles this transport showed
simple saturation kinetics, with an apparent Vmax of 700 pmol
Fig. 3. (A) Effect of CD and sterol-CD complexes on the ATP-dependent transport of MTX in inside-out Sf9 membrane vesicles. Isolated membranes were
preincubated for 10 min at 4 °C with CD or with the indicated concentrations of CD–lipid complexes, including cholesterol-CD, sitosterol-CD, ergosterol-CD, or
hydrocortisone-CD. MTX uptake was measured at 100 μM MTX concentration for 5 min at 37 °C in membrane vesicles containing the human wild-type ABCG2
(WT), or R482G–ABCG2 (G) transporter. ABCG2-dependent transport was calculated by subtracting MTX uptake measured in the presence of 1 μM Ko143. Light
gray columns: 1 mM CD or sterol-CD, dark gray columns: 4 mM CD or sterol-CD. The respective structures of the sterols applied are shown in the right panel.
(B) Effect of cholesterol and sitosterol loading on ATP-dependent MTX uptake in Sf9 membrane vesicles preloaded with sterol-CD complexes. MTX uptake was
measured at 100 μMMTX concentration for 5 min at 37 °C in membrane vesicles containing the human wild-type ABCG2 (WT), or R482G–ABCG2 (G) transporter.
Dark columns: vesicular MTX transport without inhibitor, striped columns: MTX transport in the presence of the specific ABCG2 inhibitor, Ko143 (1 μM). Part 1
demonstrates MTX uptake in the unloaded, control vesicles (containing 8 μg cholesterol/mg membrane protein), Part 2 shows MTX uptake in cholesterol-cyclodextrin
(C-CD) pre-treated vesicles (containing 56 μg cholesterol/mg membrane protein), and Part 3 shows MTX uptake in empty cyclodextrin (CD) pre-treated vesicles
(containing 5 μg cholesterol/mg membrane protein). Part 4 shows the effect of sitosterol loading on ATP-dependent MTX uptake in Sf9 membrane vesicles, when the
vesicles were pre-treated with sitosterol-beta-cyclodextrin (S-CD), similarly to the CD or C-CD pre-treatments. The mean values±SD are presented. Significant
differences are indicated by stars.
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ESG was about 45 μM. In the control Sf9 membrane vesicles
ESG uptake was too low for a proper estimation of Km. An
apparent saturation of this uptake was also achieved above
100 μM ESG, with an apparent Vmax of less than 50 pmol
ESG/mg membrane protein/min.These experiments suggest that modulation of the MTX and
ESG transport by membrane cholesterol has a predominant
effect on the Vmax, that is increasing the substrate transport
capacity of this active transporter. Cholesterol may also slightly
modulate the substrate affinity and the transporter/substrate
interactions, but we need further studies in this respect.
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transport in inside-out Sf9 cell membrane vesicles by different
membrane cholesterol levels. The effect of cholesterol on the
vesicular transport was measured at MTX and ESG concentra-
tions (50 μM MTX and 25 μM ESG, respectively) below
saturating values. In these experiments pooled membrane
preparations, containing the same amount of human ABCG2,
but loaded to different cholesterol levels, were applied.
Although a slight difference in these activation curves may be
observed, the effect of cholesterol on both ABCG2-dependent
MTX and ESG transport was maximum above 55 μg
cholesterol/mg membrane protein. Thus cholesterol modulation
of ABCG2 transport activity was the most pronounced in the
range of physiological cholesterol levels in various mammalian
cellular membranes (see Discussion).The experiments shown in Fig. 4 demonstrate that increased
membrane cholesterol did not convert the ABCG2–R482G
mutant into an efficient MTX or ESG transporter. However, in
order to further explore the effect of cholesterol on the substrate
specificity of the mutant and wild-type ABCG2, we have also
examined Rhodamine 123 (R123) uptake by the Sf9 membrane
vesicles. R123 is a transported substrate of the ABCG2–R482G
variant, while this compound is practically not transported by
the wild-type protein. As shown in Fig. 5, MgATP-dependent,
rapid vesicular R123 uptake was well measurable by flow
cytometry in Sf9 membrane vesicles, expressing the human
R482G–ABCG2 protein. This transport was fully inhibited by
1 μM Ko143. Under the same conditions membrane vesicles
containing the wild-type ABCG2 showed no measurable R123
uptake. Also, no such ATP-dependent Rhodamine uptake was
observed in the control, beta-galactosidase expressing Sf9
membrane vesicles.
These data indicate that cholesterol loading of the vesicles
(in these experiments to 55–62 μg cholesterol/mg membrane
protein) did not evoke R123 uptake in the vesicles containing
the wild-type ABCG2, while slightly increased (as an average
by 25–30%) both the initial rate and the maximum level of the
R123 uptake in the R482G–ABCG2 vesicles. This effect was
negligible as compared to the cholesterol effect seen on the
MTX or ESG transport activity of the wild-type ABCG2
transporter. We have performed these experiments with similar
results with three independent membrane preparations, both at
22 °C and 37 °C, and in Fig. 5 we show a representative
experiment, performed in triplicates, at 22 °C.Fig. 4. Effect of cholesterol loading on ATP-dependent MTX and ESG uptake in
Sf9 membrane vesicles. MTX and ESG uptake was measured for 5 min at 37 °C
at 5 mM ATP in membrane vesicles containing the human wild-type ABCG2
(WT), or R482G–ABCG2 (G) transporter. During this time period drug uptake
was linear. The mean values±SD are presented. Panel A MTX concentration
dependence of MTX uptake. ABCG2-specific uptake at each substrate
concentration was calculated by subtracting the rate obtained in the presence
of 1 μM Ko143 ABCG2 inhibitor. ▪—MTX uptake in the control vesicles
(8 μg cholesterol/mg membrane protein), containing the human wild-type
ABCG2 (WT) transporter, •—MTX uptake in cholesterol-loaded vesicles
(56 μg cholesterol/mg membrane protein), containing the human wild-type
ABCG2 (WT) transporter, ▴—MTX uptake in the control vesicles (8 μg
cholesterol/mg membrane protein), containing the human R482G ABCG2 (G)
transporter, ▵—MTX uptake in cholesterol-loaded vesicles (62 μg cholesterol/
mg membrane protein), containing the human R482G ABCG2 (G) transporter.
Panel B ESG concentration dependence of ESG uptake. ▪—ESG uptake in the
control vesicles (8 μg cholesterol/mg membrane protein), containing the human
wild-type ABCG2 (WT) transporter, □—ESG uptake in the control vesicles
(8 μg cholesterol/mg membrane protein), containing the human wild-type
ABCG2 (WT) transporter, in the presence of 1 μM Ko143,•—ESG uptake in
cholesterol-loaded vesicles (56 μg cholesterol/mg membrane protein), contain-
ing the human wild-type ABCG2 (WT) transporter, ○—ESG uptake in
cholesterol-loaded vesicles (56 μg cholesterol/mg membrane protein), contain-
ing the human wild-type ABCG2 (WT) transporter, in the presence of 1 μM
Ko143. Panel C Relative stimulation of MTX and ESG transport by cholesterol
loading in Sf9 membrane vesicles. MTX uptake (•) was measured at 50 μM
MTX concentration, while ESG transport (□) was measured at 25 μM ESG, for
5 min at 37 °C, in Sf9 membrane vesicles containing the human wild-type
ABCG2. Membranes from the same cell preparation, containing identical
amount of ABCG2, were pre-loaded by variable C-CD concentrations to
contain different levels of cholesterol. On the figure for each data point the
mean values±SD are presented.
Fig. 5. Effect of cholesterol loading on ATP-dependent Rhodamine 123 (R123)
uptake in Sf9 membrane vesicles. R123 uptake was measured by flow cytometry
(see Materials and methods) at 1 μM R123 concentration, by taking 30-s time
points for 5 min at 22 °C in membrane vesicles containing the human wild-type
ABCG2 (WT), or R482G–ABCG2 (G) transporter. The figure shows a repre-
sentative experiment, depicting the mean values of a triplicate measurement.
The SD values for these data points were within the size of the symbols. ▪—
R123 uptake in the control vesicles (8 μg cholesterol/mg membrane protein),
containing the human wild-type ABCG2 (WT) transporter,•—R123 uptake in
cholesterol-loaded vesicles (56 μg cholesterol/mg membrane protein), contain-
ing the human wild-type ABCG2 (WT) transporter, ▴—R123 uptake in the
control vesicles (8 μg cholesterol/mg membrane protein), containing the human
R482G ABCG2 (G) transporter,▾—R123 uptake in cholesterol-loaded vesicles
(62 μg cholesterol/mg membrane protein), containing the human R482G
ABCG2 (G) transporter. ×—R123 uptake in cholesterol-loaded vesicles (62 μg
cholesterol/mg membrane protein), containing the human R482G ABCG2 (G)
transporter, in the presence of 1 μM Ko143.
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increased substrate transport by the wild-type ABCG2, while
we found no major changes by cholesterol in the substrate
handling properties of the mutant ABCG2 protein variants.
3.4. Membrane ATPase measurements
In the following experiments we examined the effect of
cholesterol loading on the membrane ATPase activity of the
ABCG2 and the MDR1 proteins. Vanadate-sensitive membrane
ATPase activity, selectively blocked by a specific inhibitor,
reflects the transport activity of a number of the ABC multidrug
transporters [1,5,39]. As reported earlier, the ABCG2-ATPase
activity can be specifically inhibited by Fumitremorgin C or its
analog, Ko143. This “basal”ABCG2-ATPase activity is relatively
high in isolated Sf9 cell membrane vesicles, but a significant
substrate-activation could not be detected in the case of the wild-
type protein in the Sf9 cell membrane preparations. In contrast,
many substrates caused a strong activation for the ABCG2-
ATPase of the R482G or R482T variants [9,14]. The significant
substrate-stimulation of the humanMDR1-ATPase activity in Sf9
membranes has also been extensively documented [4,39].
Fig. 6A shows the vanadate-sensitive ATPase activity of the
wild-type ABCG2 as well as the R482G and the R482T
variants, both in the absence and presence of two potential
transported substrates. In these studies we selected prazosin,
and the EKI-785 tyrosine kinase inhibitor (EKI), as thesecompounds were shown to be substrates both for the wild-type,
as well as the R482G or R482T variants of ABCG2 [14,35].
In Fig. 6A we document the respective ATPase activities
measured at two different membrane cholesterol levels, that is in
the control (6–8 μg cholesterol/mg membrane protein) and
cholesterol-loaded (50–65 μg cholesterol/mg membrane pro-
tein) Sf9 cell membranes, respectively. Ko143 was shown to
fully and selectively inhibit the transport activities in all these
ABCG2 variants [14], and the level of the endogenous
vanadate-sensitive ATPase activity in the control Sf9 cell
membranes was in the range of that measured in the presence of
Ko143 in the ABCG2 expressing membranes (about 8–
10 nmol/mg membrane protein/min). These data indicate that
the Ko143 sensitive fraction of the membrane ATPase activity
closely correlates with the activity of the ABCG2 protein.
As documented in Fig. 6A, cholesterol loading of the Sf9 cell
membranes did not significantly affect, or only slightly increased
the basal ATPase activity of all the three ABCG2 variants, and
did not affect the low background ATPase activity measured in
the presence of Ko143. However, cholesterol loading greatly
increased the drug-stimulated ATPase activity of the wild-type
ABCG2 in the presence of both substrates, while it had no such
effect in the case of the R482G or R482T mutant variants. Thus,
the effect of cholesterol on the drug-stimulated ATPase activity is
in close correlation with the observed alterations in the direct
vesicular substrate transport, while the basal ATPase activity may
not be directly related to this transport.
In the following experiments we have examined the effects
of several transported substrates on the ABCG2-ATPase activity
(the Ko143-sensitive fraction) in isolated Sf9 cell membranes in
a concentration range of 0.1–50 micromolar. According to our
earlier studies [14,35], in this system we did not observe, or
obtained only a minor stimulation of the ABCG2-ATPase
activity by the compounds examined. As shown in Fig. 6B, the
compounds already indicated to be transported substrates of
ABCG2, that is the tyrosine kinase inhibitor Iressa (Gefitinib),
the widely applied topotecan, the irinotecan metabolite SN38,
the experimental anticancer agent flavopiridol, and the
flavonoid compound quercetin, all produced a major stimula-
tion of the ABCG2-ATPase activity in the cholesterol-loaded
Sf9 cell membranes (Panel II), while there was only a small
stimulation in the control membranes (Panel I). In the case of
quercetin and some tyrosine kinase inhibitors this stimulation
was observed already in sub-micromolar concentrations and
produced very high maximum ATPase activity levels. These
data show that in cholesterol-loaded Sf9 membranes ABCG2
substrate screening, based on measuring Ko143-sensitive
ATPase activity, can be efficiently and reliably performed.
This is an important practical point in drug development studies,
as the Sf9 membrane system is a powerful method for
measuring substrate modulation or inhibition of ABC transpor-
ter ATPase activity, due to the much higher and well-controlled
expression level of membrane proteins than achievable in
mammalian cell membranes.
Fig. 6C shows the membrane cholesterol content dependence
of the percent drug-stimulation of the ABCG2-ATPase activity
by prazosin and EKI. In the case of the wild-type ABCG2, drug-
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cholesterol levels. Although the cholesterol dependence of this
modulation was somewhat different for the two substratemolecules applied, a maximum effect of membrane cholesterol
above 40 μg cholesterol/mg membrane protein was observed in
both cases. Fig. 6C also depicts the effect of membrane
Fig. 7. Effect of cholesterol loading on the formation of the catalytic intermediate
(nucleotide trapping) of human ABCG2 in isolated Sf9 membrane preparations.
8-azido-nucleotide trapping by the human, wild-type ABCG2 protein, expressed
in Sf9 cell membranes, was measured as described in Materials and methods, in
the presence of 2.5 μM Co-8-azido-ATP (containing alpha-32P-8-azido-ATP) at
37 °C for 2 min. Following UV-irradiation, gel-electrophoresis and electroblot-
ting, the labeled bands were visualized by Phospho-Imager. The arrow indicates
the position of the ABCG2 protein identified by immunoblotting. Isolated Sf9
cell membranes, containing the same amount of wild-type ABCG2 protein were
loaded with cholesterol by preincubation with 4 mM C-CD, as described in the
Materials and methods. Cholesterol-loaded membrane vesicles contained 50 μg
cholesterol/mg membrane protein, while the control membranes contained 8 μg
cholesterol/mg membrane protein. The concentration of EKI or Ko143 was
1 μM, the concentration of prazosin was 20 μM in the assay. The figure shows a
representative experiment.
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activity of the ABCG2–R482G variant. In the case of this mutant
transporter, increasing membrane cholesterol levels caused only
a slight decrease in the relative substrate stimulation.
In experiments not documented here in detail, we have
repeated these experiments with human MDR1-containing Sf9
membrane vesicles, and analyzed the verapamil-stimulation of
the MDR1-ATPase under various cholesterol loading condi-
tions. We found that the basal activity of the MDR1-ATPase
was slightly increased, while the verapamil-stimulated max-
imum ATPase activity, measured at 50 μM verapamil, was
practically unchanged in cholesterol-loaded Sf9 membranes. A
detailed study on the cholesterol modulation of MDR1 and
MRP1 activities is underway in our laboratory.
3.5. Nucleotide trapping measurements
In order to explore the molecular mechanism of the cholesterol
effect on human ABCG2, we examined the vanadate-sensitive
nucleotide trapping in the control and the cholesterol-loaded
isolated Sf9 cell membranes, respectively. Most active ABC
transporters form a catalytic intermediate, stabilized by the
presence of vanadate, which can be visualized through UV-
dependent photo-cross-linking and covalent labeling by alpha
32P-8-azido-ATP [1,3,4]. As we documented earlier [17], in
the case of ABCG2 this experiment requires the use of Co-
alpha 32P-8-azido-ATP, and nucleotide trapping is entirely
vanadate-dependent.
In our earlier nucleotide trapping experiments, carried out in
human ABCG2-containing Sf9 cell membranes, we found that
in the case of wild-type ABCG2 the addition of drugs, e.g.
prazosin, did not increase, but rather slightly decreased the
formation of this intermediate (see 17). In contrast, nucleotide
trapping in the ABCG2–R482G variant was significantly
increased by transported substrates.
In the current study we repeated these experiments in Sf9 cell
membranes, expressing ABCG2, either without or with
cholesterol preloading. As shown in Fig. 7, in the control Sf9Fig. 6. Effect of cholesterol loading on the ATPase activity of ABCG2 in isolated Sf9
sensitive ATPase activity in isolated Sf9 membrane preparations. ATPase activity in th
wild-type ABCG2 (WT), the R482G–ABCG2 (R482G), or the R482T–ABCG2 (R
substrates of the ABCG2 transporter were examined. Prazosin was applied in 20 μM
specific ABCG2 inhibitor was measured at 1 μM concentration. The mean values±S
protein, while cholesterol-loaded membranes contained 56 μg cholesterol/mg membra
in the case of the ABCG2–R482G, and 65 μg cholesterol/mg membrane protein in t
black columns: 1 μMEKI, light gray columns: 20 μM prazosin, striped columns: 1 μM
drugs on the ABCG2ATPase activity in control (Panel I) and in cholesterol loaded (Pa
at 37 °C in membranes containing the human wild-type ABCG2, either without chole
specific ATPase activity was determined as the Ko143-sensitive fraction of the activi
methods. Each drug was tested in at least two independent membrane preparations, t
measurements. The control membranes contained 8 μg cholesterol/mg membrane prot
membrane protein. □—Quercetin, ●—EKI-785, ▵—Iressa, ▾—Prazosin, ⋄—To
content on the substrate stimulation of the ABCG2 ATPase activity in Sf9 membranes
human wild-type ABCG2 (WT), or the R482G–ABCG2 (R482G) transporter. The spe
Cholesterol loading by C-CD was achieved as described in Materials and methods.
•—Per cent stimulation of the Ko143-sensitive ATPase activity by 20 μM Prazosin
Per cent stimulation of the Ko143-sensitive ATPase activity by 1 μM EKI in memb
stimulation of the Ko143-sensitive ATPase activity by 20 μM Prazosin in mem
stimulation of the Ko143-sensitive ATPase activity by 1 μM EKI in membranes ccell membranes vanadate-dependent nucleotide trapping was
well measurable, but the addition of prazosin or EKI only
slightly decreased the formation of this intermediate. When
calculating the average values in three independent experi-
ments, corrected by the immunoblot loading control of ABCG2,
the relative ABCG2 labeling was decreased to 45% by prazosin
and to 55% by EKI. Cholesterol loading did not alter the basic
level of ABCG2-nucleotide trapping (the mean relative value of
ABCG2 labeling was 105%). However, the addition of prazosin
(a relative increase to 125%), or even more significantly, of EKI
(an increase to 180%), stimulated nucleotide trapping in the
cholesterol-loaded membranes, in contrast to the strongmembrane preparations. Panel A Effect of cholesterol loading on the vanadate-
e vesicles was measured for 20 min at 37 °C in membranes containing the human
482T) transporter. The basal ATPase activity and the effects of two potential
concentration, EKI was used in 1 μM concentration. The effect of Ko143, a
D are presented. Control membranes contained 8 μg cholesterol/mg membrane
ne protein in the case of the wt ABCG2, 62 μg cholesterol/mg membrane protein
he case of the ABCG2–R482 T variant. Empty columns: basal ATPase activity,
Ko143. Panel B Concentration dependence of the stimulatory effect of different
nel II) Sf9 cell membrane preparations. ATPase activity was measured for 20 min
sterol-loading (left panel) or loaded with cholesterol (right panel). The ABCG2-
ty. Cholesterol loading by C-CD was achieved as described in the Materials and
he mean±SD values are presented in a representative experiment with triplicate
ein, while cholesterol-loaded membrane vesicles contained 42 μg cholesterol/mg
potecan, ♦ Flavopiridol, ×—SN-38. Panel C Effect of membrane cholesterol
. ATPase activity was measured for 20 min at 37 °C in membranes containing the
cific ATPase activity for ABCG2was calculated as the Ko143-sensitive fraction.
The mean values obtained in three independent experiments±SD are presented.
in membranes containing the human wild-type ABCG2 (WT) transporter, ▪—
ranes containing the human wild-type ABCG2 (WT) transporter, ○—Per cent
branes containing the human R482G ABCG2 (G) transporter, □—Per cent
ontaining the human R482G ABCG2 (G) transporter.
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membranes. Similar results were obtained at two different time-
points (2 min and 5 min) in these nucleotide trapping studies. In
all cases the addition of Ko143 eliminated ABCG2-dependent
nucleotide trapping.
In the case of the ABCG2–R482G mutant variant, prazosin
and EKI stimulation of nucleotide trapping was already present
in the control membranes [17], and in this case we did not find
any significant difference by cholesterol enrichment of the Sf9
cell membranes in the present study (data not shown).
These experiments indicate a significant effect of membrane
cholesterol on the rate of nucleotide trapping by the human
ABCG2 protein. In correlation with the observed acceleration of
direct vesicular substrate transport, and the appearance of drug-
stimulated ATPase activity, cholesterol loading was found to
promote the drug stimulation of the formation of the catalytic
intermediate, indicating a cholesterol stimulation of the turnover
of the wild-type transporter.
4. Discussion
Our present experiments document a major effect of
membrane cholesterol on the activity of the human ABCG2
protein. We found that in intact mammalian cells a rapid and
mild cholesterol depletion, without causing a significant cellular
damage, strongly reduced ABCG2-dependent transport activity.
This effect was fully reversible, and selective for the wild-type
ABCG2, while the function of the highly active mutant variant
ABCG2–R482G, found in drug-selected tumor cells, was not
influenced by a similar cholesterol depletion. It is important to
note that cell viability or membrane localization of ABCG2 was
unchanged in the course of these cholesterol modulating
experiments. Moreover, under similar conditions we found no
measurable effect of cholesterol depletion or cholesterol loading
on the activity of another ABC multidrug transporter, the
MDR1 (ABCB1) protein.
In intact cells several non-specific effects may occur, including
the removal of various hydrophobic membrane components by
cyclodextrin. Moreover, long-term cholesterol depletion signifi-
cantly reduces survival, thus drug-resistance experiments could
not be performed under these conditions. Therefore, themolecular
details of cholesterol effects could be much better examined in
isolated membrane preparations. In order to perform such studies
we used Sf9 cell membrane vesicles, obtained from insect cells
expressing high levels of the human ABCG2 or its variants. Sf9
cell membranes contain relatively low levels of endogenous
cholesterol, thus variable levels of increased membrane choles-
terol, approaching or even exceeding those in mammalian cell
membranes, could be achieved.
Direct vesicular transport studies performed in such prepara-
tions indicated that the maximum transport rate of ABCG2 can
be increased up to 20 fold by increasing membrane cholesterol
levels. By using various sterol-cyclodextrin complexes we
found that this effect on ABCG2 was selective for alterations in
membrane cholesterol. Although the structurally similar ergos-
terol or sitosterol also have the capacity to increase membrane
order in artificial membranes, and they have a stabilizing role indrosophila (ergosterol) or plant (sitosterol) membranes [see refs.
[34,42,50], none of them were able to mimic the effect of
cholesterol in our experiments. Similarly to that seen in intact
cells, this effect of membrane cholesterol was absent in the case
of the R482G mutant variant of the transporter.
Vanadate- and inhibitor-sensitive membrane ATPase activity
in ABC transporter expressing cell membrane preparations has
been shown to correlate with the transport activity of these
proteins [5]. However, according to our earlier experiments, in
the case of the wild-type ABCG2 transporter, in spite of a
pronounced basal ATPase activity, the substrate drug stimula-
tion in the Sf9 cell membranes was relatively small [14]. In
contrast, in isolated mammalian cell (e.g. MCF7) membranes,
ABCG2-ATPase activity could be significantly stimulated by
various drug substrates. It has been suggested for MDR1 and for
ABCG2 as well, that the basal ATPase activity, measured in the
absence of added substrates, may be due to activation by
endogenous substrates, or may reflect a partially uncoupled
ATPase activity of the transporter [1,4]. Interestingly, the
ATPase activity of the R482G or R482T mutant variants of
ABCG2 could be significantly enhanced by the respective
substrate drugs both in the Sf9 and the mammalian cell
membrane preparations [10,14].
Since membrane proteins, when expressed in Sf9 cells, are
underglycosylated, we first speculated that the loss of
glycosylation may result in these alterations of the ABCG2-
ATPase activity. However, it has been demonstrated that
glycosylation of ABCG2 has no effect either on its activity,
processing, or membrane localization [46–48]. The present
experiments strongly suggest that alterations in ABCG2-
ATPase are mostly due to the different membrane cholesterol
levels, that is cholesterol enrichment of the Sf9 cell membranes
enables a substrate-stimulation of the wild-type ABCG2-
ATPase activity. An important result of these experiments is
that by using cholesterol preloaded Sf9 cell membranes this
technology allows the screening of a wide variety of ABCG2-
specific substrate molecules by measuring ABCG2-ATPase
activity. This is clearly shown by the large effects of
submicromolar concentrations of e.g. Gefitinib (Iressa), or
quercetin in this system (see Fig. 6B-II).
Earlier we examined the vanadate-dependent formation of a
trapped nucleotide by ABCG2, reflecting the catalytic inter-
mediate in ABC transporters in isolated Sf9 cell membrane
preparations [17]. In these experiments we found that in the case
of the wild-type ABCG2 protein, the transported substrates did
not increase, rather slightly decreased the formation of this
intermediate. In contrast, transported substrates significantly
increased nucleotide trapping by the ABCG2-R482G variant
[17]. In our present experiments we found that in cholesterol
enriched Sf9 cell membranes transported substrates produced an
increased rate of catalytic intermediate formation also in the
wild-type ABCG2. This finding indicates that cholesterol
enhances the drug substrate-dependent turnover of ABCG2.
In this study we observed that the effect of membrane cho-
lesterol was specific for the wild-type ABCG2 protein, containing
an Arg (R) at the proposed intracellular membrane region of
the third transmembrane loop of the protein. Replacement of this
2711Á. Telbisz et al. / Biochimica et Biophysica Acta 1768 (2007) 2698–2713Arg by Gly or Thr significantly alters the substrate specificity of
ABCG2, and seems to removes its cholesterol modulation. This
finding excludes a non-specific stabilization or modulation of this
protein by cholesterol, and suggests a special role of this protein
region both in the substrate recognition and cholesterol modula-
tion of ABCG2. A recent study [48,49] concluded that mutations
at position 482 in ABCG2, while alter the transport and ATPase
profile of this protein, do not affect drug binding. Thus cholesterol
may interact with a region involved in the catalytic/transport
region of ABCG2. An exploration of the exact molecular or
conformational specificity of this cholesterol effect needs further
experiments.
Based on Sf9 membrane ATPase measurements, earlier we
proposed that the R482G and R482T variants of ABCG2 may
have “gain-of-function” properties [14]. Our present experi-
ments indicate that these mutant ABCG2 variants may show a
higher ATPase and transport activity only in the cholesterol-
poor membranes, and at increasing membrane cholesterol levels
in the Sf9 cell membranes the wild-type protein may achieve an
ATPase and transport capacity approaching that in the mutant
variants. We speculate that in spite of the reduced xenobiotic
recognition profile of the wild-type ABCG2, its cholesterol-
modulation may explain the evolutionary conservation of Arg at
position 482.
In these experiments we observed gradual effects of the Sf9
cell membrane cholesterol on the transport and ATPase activity
of ABCG2. The range where membrane cholesterol had the
most significant effect, in mammalian cells corresponds to the
values observed between the low-cholesterol intracellular (e.g.
ER) membranes, and the high-cholesterol plasma membranes
[50]. Certain plasma membrane microdomains (e.g. “membrane
rafts”) were shown to have especially high cholesterol levels
[34,50]. Thus in mammalian cells a complex, reversible
cholesterol modulation of the ABCG2-dependent xenobiotic
extrusion or cancer drug resistance may be expected. The
routing of the ABCG2 protein to specific plasma membrane
regions, or the internalization of the protein to intracellular
membrane compartments, may alter ABCG2 transport activity
by more than an order of magnitude.
Several members of the ABCG family are involved in active
cholesterol transport [51–53], and this may be true for ABCG2
as well. However, direct vesicular cholesterol transport
measurements could not be performed in our system. Still, the
present study does not suggest that cholesterol itself is a
transported substrate for ABCG2. We did not observe any
cholesterol competition in the transport assays, and found no
major stimulation of the ABCG2-ATPase activity or nucleotide
trapping by cholesterol in the absence of added substrates.
However, a possible co-transport of cholesterol with specific
ABCG2 substrates cannot be excluded at present.
Cholesterol modulation of multidrug transporters, especially
that of MDR1 (ABCB1) has been reported in the literature
[29,30]. In our present study, under similar conditions as
examined for ABCG2, we found no major effect of the mild
cholesterol depletion of mammalian cell membranes on the
MDR1 transport activity (see Fig. 1A). In experiments to be
reported in detail elsewhere, we have examined the effects ofmembrane cholesterol both on the human MDR1 and the MRP1
proteins, expressed in Sf9 cell membrane preparations. How-
ever, under conditions used in the present study, the effect of
membrane cholesterol on these transporters was almost
negligible, as compared to the wild-type human ABCG2. In
earlier studies with isolated MDR1 protein it has been shown
[54] that cholesterol increased the basal ATPase activity but did
not significantly modulate the drug-stimulated MDR1-ATPase
in proteoliposomes. In a similar system, recent experiments
documented that cholesterol directly and variably modulated the
drug-affinity of the isolated MDR1 protein, while did not affect
its maximum turnover rate in the case of most substrates, having
high stimulatory activity. Paclitaxel, a substrate with a low
stimulatory effect, was found to be an exception [55].
As a summary, here we found that membrane cholesterol
depletion inhibits, while cholesterol enrichment greatly aug-
ments the active transport and ATPase activity, as well as the
catalytic intermediate formation of the ABCG2 protein.
Detailed studies on these cholesterol effects, regarding various
toxin and drug substrates, as well as the polymorphic variants of
ABCG2, are underway in our laboratory. These combined
studies may allow the exploration of a functional, complex
regulation of this medically important ABC transporter protein.
5. Note added in proof
While this manuscript was under reviewing, a communica-
tion (Ref. [56]) described a stimulating effect of cholesterol
loading on the ABCG2 ATPase and transport activity in isolated
membrane preparations.
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